#112: BIO's Rich Masters on the Future of Biotech and the International Convention
Listen now
Description
Navigating the biotech industry's rapid advancements and complex regulations can be daunting. High-stakes investments and the pressure to innovate further add to the challenge. Rich Masters, the CMO of BIO (Biotechnology Innovation Organization), is a seasoned expert in this field. His role in organizing the BIO International Convention and his extensive industry experience equips him with unique insights to tackle these challenges. In this fantastic podcast episode, we delve into: 🔬 The behind-the-scenes experience of organizing and attending the BIO International Convention 2022 in San Diego. 🔬 Rich's journey to the helm of BIO as CMO and his vision for the organization. 🔬 The meticulous preparations for the upcoming BIO International Convention 2023 in Boston, anticipated to be a landmark event in the biotech calendar. 🔬 The innovative features and services introduced for the BIO International Convention 2023, including the BIO Podcast series and the BIO News platform. 🔬 Rich's perspective on the future of the biotech industry, discussing potential challenges and opportunities for 2024 and beyond. 💡 LINKS TO MORE CONTENT Youtube Christian Soschner: Rich Masters 📖 Memorable Quotes: (13:50) "The majority of biomedical and drug innovation investments fail... This ecosystem is crucial and needs protection." (15:00) "Developing a drug is an expensive process... Without investment, the engine of innovation stalls, we don't see new drugs on the market." (16:38) "If you price fix these drugs, you are going to stop the cures of the future." (20:01) "What we're witnessing worldwide is an attack from socialist-minded groups against intellectual property, our only asset." (26:18)"Our main focus may be on Washington, but we work closely with our International Biotech Association based in Brussels. We have numerous international partners." (29:09) "As the next pandemic looms, the question is, do we want all drug development concentrated in one country, or a viable drug development market in the West?" (42:12) "We can't continue to stifle innovation and science and then expect to create the next generation of cures... we're eliminating entire classes of diseases." (44:10) "Biotechnology provides the solution for eliminating food insecurity, transitioning from fossil fuels to green energy sources, and ending disease... we need to establish policies that encourage, rather than stifle, innovation." ⏰ Timestamps: (03:45) - [Recap: BIO Convention Collaboration Success] (05:18) - [BIO Event Excellence: Future Planning Insights] (10:36) - [Inside BIO: CMO's Role & Event Portfolio] (17:05) - [Decoding Biomedical Investment Ecosystem] (20:31) - [Behind BIO Conventions: Passion & Effort] (22:15) - [Biotech Investment: Price Fixing & IP Challenges] (27:41) - [Capital Formation in Biotech: Navigating Economic Shifts] (29:33) - [Global Biotech Politics: Washington & Brussels Focus] (32:24) - [Future of Drug Development: Market Shift Navigation] (35:32) - [BIO 1-1 Partnering: Revolutionizing Biotech Startup Growth] (42:54) - [Policy Impact & Transition to Physical Conventions] (47:25) - [Biotech Solutions: Hunger, Climate, Disease] (51:32) - [Bio Convention Revolution: Aggressive Marketing Strategy] (55:57) - [Middle East Evolution in Global Innovation Scene] (59:30) - [Balancing Attendee Expectations: The Art & Challenges] (01:03:32) - [Diverse Voices: Crafting an Inclusive BIO Speaker Line-up Support the showDo you want to support the podcast team? Join the LSG2G Newsletter as a paying member: Link
More Episodes
Send us a Text Message.Unlock the secrets of future-proof investing and transformative innovation in this compelling episode. Join us as we delve into the mind of Luis Pareras, Managing Partner at Invivo Partners, a venture capital fund pioneering investments in cutting-edge biotech. Discover how...
Published 05/31/24
Published 05/31/24
Send us a Text Message.What if there was a funding source that could supercharge your startup's growth without diluting your equity? It's not a pipe dream. It's venture debt – a powerful tool that many founders and investors haven't fully explored.In this episode, we channel the spirit of...
Published 05/21/24